| Literature DB >> 26989863 |
Junzheng Du1, Shanshan Xing1, Zhancheng Tian1, Shandian Gao1, Junren Xie1, Huiyun Chang1, Guangyuan Liu1, Jianxun Luo1, Hong Yin1,2.
Abstract
Bluetongue virus (BTV) causes a non-contagious, arthropod-transmitted disease in wild and domestic ruminants, such as sheep. In this study, we used iTRAQ labeling coupled with LC-MS/MS for quantitative identification of differentially expressed proteins in BTV-infected sheep testicular (ST) cells. Relative quantitative data were obtained for 4455 proteins in BTV- and mock-infected ST cells, among which 101 and 479 proteins were differentially expressed at 24 and 48 h post-infection, respectively, indicating further proteomic changes during the later stages of infection. Ten corresponding genes of differentially expressed proteins were validated via real-time RT-PCR. Expression levels of three representative proteins, eIF4a1, STAT1 and HSP27, were further confirmed via western blot analysis. Bioinformatics analysis disclosed that the differentially expressed proteins are primarily involved in biological processes related to innate immune response, signal transduction, nucleocytoplasmic transport, transcription and apoptosis. Several upregulated proteins were associated with the RIG-I-like receptor signaling pathway and endocytosis. To our knowledge, this study represents the first attempt to investigate proteome-wide dysregulation in BTV-infected cells with the aid of quantitative proteomics. Our collective results not only enhance understanding of the host response to BTV infection but also highlight multiple potential targets for the development of antiviral agents.Entities:
Keywords: BTV; Differential expression; Microbiology; Quantitative proteomics; iTRAQ
Mesh:
Substances:
Year: 2016 PMID: 26989863 PMCID: PMC7168089 DOI: 10.1002/pmic.201500275
Source DB: PubMed Journal: Proteomics ISSN: 1615-9853 Impact factor: 3.984
Primer sequences used for real‐time RT‐PCR
| Primer name | Sequence | Product size (bp) |
|---|---|---|
| CASP8 forward | 5’‐GCACTACAGAGACCAAACAGCAA‐3’ | 142 |
| CASP8 reverse | 5’‐TTGCCCATCAGAGCCATAGA‐3’ | |
| DDX58 forward | 5’‐CAGTGCAATCTGGTCATCCTCTAC‐3’ | 84 |
| DDX58 reverse | 5’‐CCCTCTTGCTCTTCCTCTACCTC‐3’ | |
| eIF4a1 forward | 5’‐CTTGTATGAAACCCTGACCATTACC‐3’ | 82 |
| eIF4a1 reverse | 5’‐CATCTTCTCGGTGAGCCAATC‐3’ | |
| HSP27 forward | 5’‐CGCCCTGGTGTGTAACTCTTGT‐3’ | 234 |
| HSP27 reverse | 5’‐GGAAGGTGACGGGAATGGT‐3’ | |
| IFIH1 forward | 5’‐GACCTCACGGACTTGCCTTC‐3’ | 137 |
| IFIH1 reverse | 5’‐AGTTTCTCCTCCACACATTTATCCA‐3’ | |
| IFIT3 forward | 5’‐CCATACCAAACAATGCCTACCTC‐3’ | 168 |
| IFIT3 reverse | 5’‐GCCCCTTCTCAATCGCTCT‐3’ | |
| ISG20 forward | 5’‐TGCTCTGCTCACCCCAACT‐3’ | 121 |
| ISG20 reverse | 5’‐CCGTTCCCCTTTTGCTCTC‐3’ | |
| OAS1 forward | 5’‐CTCAGGGATTTCGGACTGTTTT‐3’ | 99 |
| OAS1 reverse | 5’‐GGCTAATCGTAGGGTTTTCCAAG‐3’ | |
| STAT1 forward | 5’‐GGTGAAGTTGCAAGAGCTGA‐3’ | 135 |
| STAT1 reverse | 5’‐TCCATGTTCATCACCTTCGT‐3’ | |
| RSAD2 forward | 5’‐CATCCTCGCCATCTCCTGT‐3’ | 80 |
| RSAD2 reverse | 5’‐CGTGGTTCTTCTTTCCTTGACC‐3’ | |
| β‐actin forward | 5’‐CTATGAGCTGCCCGATGGT‐3’ | 122 |
| β‐actin reverse | 5’‐TGAAGGTGGTCTCGTGGATG‐3’ |
Figure 1Confirmation of BTV infection in ST cells. (A) Morphological changes in ST cells at different time‐points after BTV infection (MOI = 0.1), with mock‐infected cells as a control. (B) Virus titers of BTV in ST cells expressed as PFU/mL on a logarithmic scale at different times post‐infection. (C) RT‐PCR validation of BTV infection in ST cells by amplifying the S7 gene.
Differentially expressed proteins identified via iTRAQ analysis of ST cells infected with BTV‐1
| Accession number | Protein name | Gene symbol | Peptide | Coverage | Infected/uninfected (24 h) ratio | Infected/uninfected (48 h) ratio |
|---|---|---|---|---|---|---|
| Proteins showing increased abundance in BTV‐infected cells | ||||||
| ENSOARP00000015710 | Radical S‐adenosyl methionine domain‐containing protein 2 | RSAD2 | 7 | 20.7 | 16.39 | 9.18 |
| ENSOARP00000011754 | Interferon‐stimulated gene 20 kDa protein | ISG20 | 2 | 11.7 | 10.53 | 14.73 |
| ENSOARP00000008103 | Protein VPRBP | VPRBP | 1 | 0.5 | 7.35 | 0.196 |
| ENSOARP00000016273 | Interferon‐induced protein with tetratricopeptide repeats 2 | IFIT2 | 8 | 18.6 | 6.25 | 7.38 |
| ENSOARP00000015874 | Interferon‐induced protein with tetratricopeptide repeats 3 | IFIT3 | 10 | 23.6 | 5.43 | 5.38 |
| ENSOARP00000009432 | Interferon beta‐2 | IFNB2 | 3 | 15.1 | 4.59 | 3.09 |
| ENSOARP00000011035 | Interferon‐induced GTP‐binding protein Mx1 | MX1 | 14 | 30.6 | 4.57 | 9.06 |
| ENSOARP00000010974 | Interferon‐induced GTP‐binding protein Mx2 | MX2 | 15 | 31.7 | 4.10* | 6.07 |
| ENSOARP00000019646 | Vascular cell adhesion protein 1 | VCAM1 | 9 | 15.2 | 3.97 | 2.59 |
| ENSOARP00000014407 | Interferon‐induced protein 44 | IFI44 | 2 | 4.4 | 3.85 | 7.46 |
| ENSOARP00000007752 | Ubiquitin‐like protein ISG15 | ISG15 | 5 | 36.7 | 3.46 | 5.07 |
| ENSOARP00000005319 | C‐C motif chemokine 5 (Fragment) | CCL5 | 1 | 9.9 | 3.44 | 2.45 |
| ENSOARP00000016282 | Interferon‐induced protein with tetratricopeptide repeats 1 | IFIT1 | 10 | 25.1 | 3.25 | 7.63 |
| ENSOARP00000019807 | Coagulation factor XIII A chain (Fragment) | F13A | 2 | 3.8 | 3.22 | 4.46 |
| ENSOARP00000006578 | Interferon‐induced helicase C domain‐containing protein 1 | IFIH1 | 5 | 4.8 | 3.18 | 6.89 |
| ENSOARP00000003061 | 2′‐5′‐oligoadenylate synthase 1 | OAS1 | 2 | 13.0 | 3.02 | 4.01 |
| ENSOARP00000001192 | Probable E3 ubiquitin‐protein ligase HERC6 | HERC6 | 2 | 2.7 | 2.89 | 4.97 |
| ENSOARP00000002385 | Indoleamine 2,3‐dioxygenase 1 | I23O1 | 3 | 8.3 | 2.79 | 7.16 |
| ENSOARP00000010460 | Interferon‐induced, double‐stranded RNA‐activated protein kinase | E2AK2 | 8 | 15.7 | 2.72 | 7.08 |
| ENSOARP00000020639 | Proteasome activator complex subunit 2 | PSME2 | 1 | 3.8 | 2.72 | 2.05 |
| ENSOARP00000018175 | Caspase‐8 | CASP8 | 5 | 10.0 | 2.59 | 4.23 |
| ENSOARP00000008124 | Antigen peptide transporter 2 | TAP2 | 13 | 23.5 | 2.58 | 1.93 |
| ENSOARP00000008309 | Antigen peptide transporter 1 | TAP1 | 11 | 20.5 | 2.53 | 2.94 |
| ENSOARP00000006537 | protein MB21D1 | CGAS | 3 | 11.7 | 2.43 | 2.46 |
| ENSOARP00000001017 | E3 ubiquitin‐protein ligase RNF213 | RN213 | 22 | 5.0 | 2.35 | 2.99 |
| ENSOARP00000002141 | Tryptophan–tRNA ligase, cytoplasmic | SYWC | 6 | 17.3 | 2.29 | 3.22 |
| ENSOARP00000015803 | Probable ATP‐dependent RNA helicase DDX58 | DDX58 | 10 | 12.8 | 2.19 | 6.87 |
| ENSOARP00000005819 | Protein NDRG1 | NDRG1 | 2 | 7.7 | 2.18 | 1.48 |
| ENSOARP00000010079 | Tapasin | TPSN | 4 | 13.1 | 2.09 | 2.00 |
| ENSOARP00000016376 | Plasminogen activator inhibitor 1 | PAI1 | 9 | 23.9 | 2.07 | 2.23 |
| ENSOARP00000015890 | Interferon‐induced protein with tetratricopeptide repeats 5 | IFIT5 | 2 | 3.7 | 2.07 | 2.12 |
| ENSOARP00000014916 | Signal transducer and activator of transcription 1 | STAT1 | 17 | 24.7 | 2.07 | 3.26 |
| ENSOARP00000004532 | Protein PML | PML | 10 | 13.5 | 2.04 | 2.50 |
| ENSOARP00000014655 | SCY1‐like protein 2 | SCYL2 | 2 | 2.9 | 1.98 | 0.95 |
| ENSOARP00000022614 | Normal mucosa of esophagus‐specific gene 1 protein | NMES1 | 4 | 48.2 | 1.94 | 2.11 |
| ENSOARP00000017858 | TPR and ankyrin repeat‐containing protein 1 | TRNK1 | 3 | 1.1 | 1.93 | 3.97 |
| ENSOARP00000014741 | Heat shock protein beta‐1 | HSP27 | 4 | 23.4 | 1.93 | 2.47 |
| ENSOARP00000009772 | 2′‐5′‐oligoadenylate synthase 2 | OAS2 | 6 | 5.3 | 1.93 | 3.33 |
| ENSOARP00000008552 | Nuclear pore complex protein Nup160 | NU160 | 5 | 4.1 | 1.90 | 1.11 |
| ENSOARP00000014392 | Interferon‐induced protein 44‐like | IF44L | 3 | 9.1 | 1.87 | 2.28 |
| ENSOARP00000008165 | Exportin‐5 | XPO5 | 3 | 2.6 | 1.85 | 2.12 |
| ENSOARP00000006076 | 26S proteasome non‐ATPase regulatory subunit 5 | PSMD5 | 4 | 7.7 | 1.85 | 1.67 |
| ENSOARP00000013906 | Unconventionnal myosin‐X | MYO10 | 6 | 3.1 | 1.81 | 1.81 |
| ENSOARP00000011613 | Rho GTPase‐activating protein 35 | RHG35 | 3 | 1.9 | 1.78 | 2.36 |
| ENSOARP00000004472 | Ubiquitin thioesterase OTUB1 | OTUB1 | 6 | 27.6 | 1.75 | 1.30 |
| ENSOARP00000017007 | Ubiquitin‐conjugating enzyme E2 N | UBE2N | 2 | 11.1 | 1.74 | 0.98 |
| ENSOARP00000021976 | EH domain‐containing protein 4 | EHD4 | 8 | 20.0 | 1.72 | 1.91 |
| ENSOARP00000013307 | Opioid growth factor receptor | OGFR | 3 | 8.4 | 1.72 | 2.97 |
| ENSOARP00000008882 | Pyridoxal‐dependent decarboxylase domain‐containing protein 1 | PDXD1 | 5 | 7.1 | 1.71 | 1.93 |
| ENSOARP00000019117 | Endoplasmic reticulum aminopeptidase 1 | ERAP1 | 7 | 7.9 | 1.71 | 1.12 |
| ENSOARP00000002728 | Activator of 90 kDa heat shock protein ATPase homolog 1 | AHSA1 | 3 | 8.6 | 1.71 | 1.19 |
| ENSOARP00000004366 | NEDD8 ultimate buster 1 (Fragment) | NUB1 | 4 | 9.1 | 1.70 | 2.50 |
| ENSOARP00000015129 | ATPase family AAA domain‐containing protein 1 | ATAD1 | 5 | 14.4 | 1.70 | 1.22 |
| ENSOARP00000007946 | Ribonuclease inhibitor | RINI | 3 | 39.2 | 1.70 | 1.42 |
| ENSOARP00000006493 | LisH domain and HEAT repeat‐containing protein KIAA1468 | K1468 | 2 | 2.6 | 1.69 | 1.48 |
| ENSOARP00000018446 | Dynamin‐2 | DYN2 | 6 | 11.8 | 1.68 | 1.78 |
| ENSOARP00000018260 | 25‐hydroxycholesterol 7‐alpha‐hydroxylase | CP7B1 | 3 | 5.5 | 1.68 | 1.32 |
| ENSOARP00000009260 | Perilipin‐3 | PLIN3 | 5 | 16.5 | 1.68 | 1.61 |
| ENSOARP00000001081 | Developmentally‐regulated GTP‐binding protein 2 | DRG2 | 3 | 11.5 | 1.67 | 2.88 |
| ENSOARP00000001415 | COMM domain‐containing protein 3 | COMD3 | 1 | 6.2 | 1.67 | 1.33 |
| ENSOARP00000019836 | Heme oxygenase 1 | HMOX1 | 5 | 24.0 | 1.64 | 1.40 |
| ENSOARP00000017457 | Negative elongation factor C/D | NELFD | 3 | 5.3 | 1.63 | 1.57 |
| ENSOARP00000000358 | Nuclear pore complex protein Nup107 | NU107 | 7 | 8.2 | 1.63 | 1.71 |
| ENSOARP00000003137 | Double‐stranded RNA‐specific adenosine deaminase | DSRAD | 12 | 11.5 | 1.63 | 2.54 |
| ENSOARP00000013662 | Ataxin‐3 | ATX3 | 2 | 5.9 | 1.63 | 2.09 |
| ENSOARP00000003736 | Tubulin‐specific chaperone E | TBCE | 3 | 6.4 | 1.63 | 1.58 |
| ENSOARP00000019486 | 2′,3′‐cyclic‐nucleotide 3′‐phosphodiesterase | CN37 | 6 | 12.8 | 1.61 | 1.02 |
| ENSOARP00000015534 | Eukaryotic initiation factor 4A‐I | eIF4A1 | 8 | 38.8 | 1.59 | 2.84 |
| ENSOARP00000020612 | Importin‐4 | IPO4 | 3 | 3.1 | 1.59 | 2.58 |
| ENSOARP00000016467 | Importin subunit alpha‐2 | IMA2 | 7 | 16.4 | 1.58 | 1.13 |
| ENSOARP00000019059 | Deubiquitinating protein VCIP135 | VCIP1 | 3 | 3.6 | 1.57 | 1.75 |
| ENSOARP00000010977 | DBIRD complex subunit KIAA1967 | K1967 | 9 | 14.2 | 1.56 | 1.80 |
| ENSOARP00000010473 | Adapter protein CIKS | CIKS | 2 | 3.7 | 1.56 | 4.25 |
| ENSOARP00000000590 | E3 SUMO‐protein ligase RanBP2 (Fragment) | RANBP2 | 12 | 4.7 | 1.56 | 1.13 |
| ENSOARP00000018654 | Guanine nucleotide‐binding protein G subunit alpha‐1 | GNAI1 | 1 | 19.0 | 1.56 | 1.52 |
| ENSOARP00000005220 | U3 small nucleolar RNA‐associated protein 15 homolog | UTP15 | 4 | 8.3 | 1.55 | 0.87 |
| ENSOARP00000013891 | Guanine nucleotide‐binding protein‐like 1 | GNL1 | 2 | 3.1 | 1.54 | 2.58 |
| ENSOARP00000013829 | Hexokinase‐2 | HXK2 | 13 | 21.7 | 1.53 | 1.96 |
| ENSOARP00000013594 | Importin‐7 | IPO7 | 6 | 7.1 | 1.52 | 1.68 |
| ENSOARP00000020750 | Ubiquitin‐like‐conjugating enzyme ATG3 | ATG3 | 3 | 11.5 | 1.52 | 1.98 |
| ENSOARP00000017974 | Nucleoporin p54 | NUP54 | 6 | 16.2 | 1.51 | 1.41 |
| ENSOARP00000019761 | Formin‐like protein 3 | FMNL3 | 10 | 10.8 | 1.51 | 1.47 |
| ENSOARP00000022035 | Macrophage‐capping protein | CAPG | 7 | 20.7 | 1.51 | 1.32 |
| Proteins showing decreased abundance in BTV‐infected cells | ||||||
| ENSOARP00000000336 | Plexin domain‐containing protein 2 | PXDC2 | 3 | 4.7 | 0.66 | 0.53 |
| ENSOARP00000019983 | Collagen alpha‐1(XI) chain | COBA1 | 6 | 5.2 | 0.65 | 0.47 |
| ENSOARP00000009036 | 39S ribosomal protein L14, mitochondrial | RM14 | 3 | 16.6 | 0.65 | 0.63 |
| ENSOARP00000007935 | Fatty acyl‐CoA reductase 1 | FACR1 | 7 | 15.1 | 0.65 | 0.47 |
| ENSOARP00000005767 | L‐allo‐threonine aldolase | LTAA | 3 | 10.2 | 0.65 | 0.70 |
| ENSOARP00000013281 | C‐type mannose receptor 2 | MRC2 | 2 | 1.8 | 0.65 | 0.54 |
| ENSOARP00000005693 | Drebrin | DREB | 9 | 19.9 | 0.63 | 0.54 |
| ENSOARP00000015742 | Acyl‐CoA desaturase | ACOD | 1 | 2.7 | 0.62 | 0.38 |
| ENSOARP00000001046 | Alpha‐2‐macroglobulin | A2MG | 13 | 10.8 | 0.58 | 1.04 |
| ENSOARP00000019765 | Peptidyl‐glycine alpha‐amidating monooxygenase | AMD | 5 | 6.2 | 0.57 | 0.66 |
| ENSOARP00000004450 | Immunoglobulin superfamily containing leucine‐rich repeat protein 2 | ISLR2 | 4 | 6.7 | 0.51 | 0.26 |
| ENSOARP00000015287 | Connective tissue growth factor | CTGF | 5 | 17.3 | 0.48 | 0.46 |
| ENSOARP00000022056 | Alpha‐2‐HS‐glycoprotein | FETUA | 2 | 4.0 | 0.40 | 1.09 |
| ENSOARP00000018386 | Keratin, type II microfibrillar (Fragment) | K2M1 | 2 | 6.3 | 0.39 | 1.29 |
| ENSOARP00000004100 | Alpha‐1B‐glycoprotein | A1BG | 3 | 5.9 | 0.30 | 1.11 |
| ENSOARP00000009080 | Serotransferrin | TRFE | 12 | 16.2 | 0.28 | 0.98 |
| ENSOARP00000015963 | Alpha‐1‐antiproteinase | A1AT | 2 | 4.8 | 0.23 | 0.96 |
| ENSOARP00000015112 | Alpha‐2‐antiplasmin | A2AP | 1 | 1.6 | 0.22 | 1.74 |
*Represents significant difference (p‐value<0.05).
Figure 2Correlation of uninfected ST cells between the two time‐points (24 and 48 hpi). The x‐axis represents the variation levels of proteins in uninfected ST cells between the two time‐points. The left y‐axis represents the frequency of quantitative proteins (histograms) and the right y‐axis represents the cumulative percentage of proteins at different variation levels (line graph).
Figure 3Confirmation of differentially expressed proteins with real‐time RT‐PCR or western blot. (A) Real‐time RT‐PCR analysis of ten selected genes in BTV‐infected cells and control samples. ST cells were infected with BTV or mock‐infected at MOI of 0.1, and collected at 24 and 48 hpi. Total RNA was extracted and reverse‐transcribed into cDNA for subsequent analysis via quantitative PCR. Fold‐change values were calculated according to the 2—ΔΔCT method, using β‐actin as an internal reference. Error bars represent the standard error of three independent experiments. (B) Western blot analysis of β‐actin, STAT1, eIF4a, and HSP27 in BTV‐infected and control samples at 24 and 48 hpi. Equal amounts of protein from BTV and mock‐infected cells were separated using SDS‐PAGE and transferred to PVDF membranes. The membranes were probed with the appropriate antibodies, and bands visualized. β‐actin was used as the internal reference. The images shown are representatives of three independent experiments. (C) The intensity ratio between the corresponding bands (BTV‐infected band/Mock band) was determined using ImageJ and normalized against β‐actin .
Figure 4GO and KEGG pathway enrichment analysis of 101 differentially expressed proteins based on their functional annotations. (A) Analysis of cellular component (GO‐CC); (B) analysis of molecular function (GO‐MF); (C) analysis of biological process (GO‐BP); (D) KEGG Pathway enrichment analysis.
Figure 5Interaction network of differentially expressed proteins generated using the STRING database. Network analysis was set at medium confidence (STRING score = 0.4). The edges represent predicted functional associations. An edge was drawn with up to seven different colored lines representing the existence of seven types of evidence used in predicting the associations. The red line indicates the presence of fusion evidence, the green line neighborhood evidence, the blue line co‐occurrence evidence, the purple line experimental evidence, the yellow line textmining evidence, the light‐blue line database evidence, and the black line co‐expression evidence.